265 related articles for article (PubMed ID: 21900362)
1. A new phage-display tumor-homing peptide fused to antiangiogenic peptide generates a novel bioactive molecule with antimelanoma activity.
Matsuo AL; Juliano MA; Figueiredo CR; Batista WL; Tanaka AS; Travassos LR
Mol Cancer Res; 2011 Nov; 9(11):1471-8. PubMed ID: 21900362
[TBL] [Abstract][Full Text] [Related]
2. A KDR-binding peptide (ST100,059) can block angiogenesis, melanoma tumor growth and metastasis in vitro and in vivo.
Rastelli L; Valentino ML; Minderman MC; Landin J; Malyankar UM; Lescoe MK; Kitson R; Brunson K; Souan L; Forenza S; Goldfarb RH; Rabbani SA
Int J Oncol; 2011 Aug; 39(2):401-8. PubMed ID: 21567086
[TBL] [Abstract][Full Text] [Related]
3. Targeting of tumor blood vessels: a phage-displayed tumor-homing peptide specifically binds to matrix metalloproteinase-2-processed collagen IV and blocks angiogenesis in vivo.
Mueller J; Gaertner FC; Blechert B; Janssen KP; Essler M
Mol Cancer Res; 2009 Jul; 7(7):1078-85. PubMed ID: 19584266
[TBL] [Abstract][Full Text] [Related]
4. Identification of synovium-specific homing peptides by in vivo phage display selection.
Lee L; Buckley C; Blades MC; Panayi G; George AJ; Pitzalis C
Arthritis Rheum; 2002 Aug; 46(8):2109-20. PubMed ID: 12209516
[TBL] [Abstract][Full Text] [Related]
5. Experimental anticancer therapy with vascular-disruptive peptide and liposome-entrapped chemotherapeutic agent.
Sochanik A; Mitrus I; Smolarczyk R; CichoĊ T; Snietura M; Czaja M; Szala S
Arch Immunol Ther Exp (Warsz); 2010 Jun; 58(3):235-45. PubMed ID: 20383751
[TBL] [Abstract][Full Text] [Related]
6. Anti-neovascular therapy using novel peptides homing to angiogenic vessels.
Oku N; Asai T; Watanabe K; Kuromi K; Nagatsuka M; Kurohane K; Kikkawa H; Ogino K; Tanaka M; Ishikawa D; Tsukada H; Momose M; Nakayama J; Taki T
Oncogene; 2002 Apr; 21(17):2662-9. PubMed ID: 11965539
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a designed vascular endothelial growth factor receptor antagonist helical peptide with antiangiogenic activity in vivo.
Basile A; Del Gatto A; Diana D; Di Stasi R; Falco A; Festa M; Rosati A; Barbieri A; Franco R; Arra C; Pedone C; Fattorusso R; Turco MC; D'Andrea LD
J Med Chem; 2011 Mar; 54(5):1391-400. PubMed ID: 21280635
[TBL] [Abstract][Full Text] [Related]
8. Vascular targeting with phage peptide libraries.
Pasqualini R
Q J Nucl Med; 1999 Jun; 43(2):159-62. PubMed ID: 10429511
[TBL] [Abstract][Full Text] [Related]
9. A novel melanoma-targeting peptide screened by phage display exhibits antitumor activity.
Matsuo AL; Tanaka AS; Juliano MA; Rodrigues EG; Travassos LR
J Mol Med (Berl); 2010 Dec; 88(12):1255-64. PubMed ID: 20802991
[TBL] [Abstract][Full Text] [Related]
10. Suppression of tumor growth by novel peptides homing to tumor-derived new blood vessels.
Asai T; Nagatsuka M; Kuromi K; Yamakawa S; Kurohane K; Ogino K; Tanaka M; Taki T; Oku N
FEBS Lett; 2002 Jan; 510(3):206-10. PubMed ID: 11801255
[TBL] [Abstract][Full Text] [Related]
11. targeted drug delivery to hepatocarcinoma in vivo by phage-displayed specific binding peptide.
Du B; Han H; Wang Z; Kuang L; Wang L; Yu L; Wu M; Zhou Z; Qian M
Mol Cancer Res; 2010 Feb; 8(2):135-44. PubMed ID: 20145035
[TBL] [Abstract][Full Text] [Related]
12. Molecular addresses of tumors: selection by in vivo phage display.
Li XB; Schluesener HJ; Xu SQ
Arch Immunol Ther Exp (Warsz); 2006; 54(3):177-81. PubMed ID: 16736105
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of tumor angiogenesis and melanoma growth by targeting vascular E-selectin.
Liu ZJ; Tian R; Li Y; An W; Zhuge Y; Livingstone AS; Velazquez OC
Ann Surg; 2011 Sep; 254(3):450-6; discussion 456-7. PubMed ID: 21795970
[TBL] [Abstract][Full Text] [Related]
14. NG2 proteoglycan-binding peptides target tumor neovasculature.
Burg MA; Pasqualini R; Arap W; Ruoslahti E; Stallcup WB
Cancer Res; 1999 Jun; 59(12):2869-74. PubMed ID: 10383148
[TBL] [Abstract][Full Text] [Related]
15. VGA1155, a novel binding antagonist of VEGF, inhibits angiogenesis in vitro and in vivo.
Ueda Y; Yamagishi T; Ikeya H; Hirayama N; Itokawa T; Aozuka Y; Samata K; Nakaike S; Tanaka M; Ono M; Saiki I
Anticancer Res; 2004; 24(5A):3009-17. PubMed ID: 15517909
[TBL] [Abstract][Full Text] [Related]
16. Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery.
Lee TY; Lin CT; Kuo SY; Chang DK; Wu HC
Cancer Res; 2007 Nov; 67(22):10958-65. PubMed ID: 18006841
[TBL] [Abstract][Full Text] [Related]
17. Phage peptide display.
Newton J; Deutscher SL
Handb Exp Pharmacol; 2008; (185 Pt 2):145-63. PubMed ID: 18626602
[TBL] [Abstract][Full Text] [Related]
18. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
[TBL] [Abstract][Full Text] [Related]
19. A specific heptapeptide from a phage display peptide library homes to bone marrow and binds to primitive hematopoietic stem cells.
Nowakowski GS; Dooner MS; Valinski HM; Mihaliak AM; Quesenberry PJ; Becker PS
Stem Cells; 2004; 22(6):1030-8. PubMed ID: 15536193
[TBL] [Abstract][Full Text] [Related]
20. Identification of TAX2 peptide as a new unpredicted anti-cancer agent.
Jeanne A; Sick E; Devy J; Floquet N; Belloy N; Theret L; Boulagnon-Rombi C; Diebold MD; Dauchez M; Martiny L; Schneider C; Dedieu S
Oncotarget; 2015 Jul; 6(20):17981-8000. PubMed ID: 26046793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
